Multiple large osteolytic lesions in a patient with systemic mastocytosis: a challenging diagnosis by Bonifacio, Massimiliano et al.
CASE REPORT
Multiple large osteolytic lesions in a patient with systemic
mastocytosis: a challenging diagnosis
Massimiliano Bonifacio1,2,† , Roberta Zanotti1,2,†, Emanuele Guardalben1, Elda Mimiola1,
Francesca Scognamiglio3, Omar Perbellini3, Giovanna De Matteis4, Luis Escribano5,6,
Patrizia Bonadonna2,7, Daniela Grigolato8, Sergio Bissoli9, Alice Parisi10, Alberto Zamo10,
Achille Ambrosetti1 & Maurizio Rossini2,11
1Department of Medicine, Section of Hematology, University of Verona, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy
2Multidisciplinary Outpatients Clinic for Mastocytosis, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy
3Department of Hematology, San Bortolo Hospital, Vicenza, Italy
4Department of Life and Reproduction Sciences, Section of Clinical Biochemistry, University of Verona, Verona, Italy
5Servicio Central de Citometria (NUCLEUS), Centro de Investigacion del Cancer (IBMCC; CSIC/USAL), Salamanca, Spain
6Department of Medicine and IBSAL, University of Salamanca, Salamanca, Spain
7Allergy Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
8Nuclear Medicine Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy
9Nuclear Medicine Unit, San Giacomo Apostolo Hospital, Castelfranco Veneto, Italy
10Department of Diagnostics and Public Health, Section of Pathological Anatomy, University of Verona, Verona, Italy
11Department of Medicine, Section of Rheumatology, University of Verona, Verona, Italy
Correspondence
Massimiliano Bonifacio, Department of
Medicine, Section of Hematology, University
of Verona, P.le L.A.Scuro 10, 37134 Verona,
Italy. Tel: +39-045-8124420;
Fax: +39-045-8027488;
E-mail: massimiliano.bonifacio@univr.it
Funding Information
No sources of funding were declared for this
study.
Received: 9 June 2017; Revised: 7 September
2017; Accepted: 18 September 2017
Clinical Case Reports 2017; 5(12): 1988–1991
doi: 10.1002/ccr3.1232
†These authors equally contributed to this
work.
Key Clinical Message
Patients with advanced variants of Systemic Mastocytosis may develop destruc-
tive bone lesions when massive mast cell (MC) infiltrates are present. Finding
of large osteolyses in indolent systemic mastocytosis, typically characterized by
low MC burden, should prompt investigations for an alternative explanation.
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Systemic Mastocytosis (SM) is a clonal disorder with com-
plex manifestations determined by the proliferation and
accumulation of neoplastic mast cells (MC) in the skin and
extracutaneous organs (mainly bone marrow, BM) and by
the release of soluble mediators. The 2016 revision to the
World Health Organization (WHO) classification of mas-
tocytosis includes seven variants: cutaneous mastocytosis,
indolent SM (ISM), smoldering SM, SM with an associated
hematologic neoplasm (SM-AHN), aggressive SM (ASM),
mast cell leukemia, and mast cell sarcoma [1].
Osteolyses are reported in 5–11% of patients with SM
[2, 3], usually associated with osteosclerotic lesions, osteo-
porosis, or both [4]. Small, asymptomatic lesions
(<0.5 cm) are reported in about 2% of ISM patients [5],
while large osteolyses and pathologic fractures represent
one of the “C-findings” defining ASM [6].
We report about a 55-year-old male hospitalized in
November 2012 for L2 vertebral fracture and diffuse bone
pain needing treatment with opioid analgesics. He had a
history of two anaphylactic reactions after bee sting, and
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he was treated with venom-specific immunotherapy since
2003. Physical examination performed upon admission
was unremarkable, except for neck erythema. He had
mild neutrophilia and thrombocytopenia and marked
increase in C-reactive protein and lactate dehydrogenase
(Table 1). Of note, serum tryptase was slightly increased
(13.2 ng/mL; normal value <11.4 ng/mL). Serum neoplas-
tic markers were all in the normal range. Bone densitom-
etry showed a reduction in T-score at lumbar spine and
femoral neck (2.2 and 1.0, respectively). CT scan
revealed multiple lytic bone lesions in the pelvis (the lar-
gest measuring 5 cm), humeri, left scapula, ribs, and
vertebral column, without osteosclerotic lesions. Positron
emission tomography/computed tomography with 2-
[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG-PET)
demonstrated an increased intensity of FDG uptake in the
bone lesions (SUV max 34 in the pelvis). Gastric and
colic endoscopies were normal, as well as thyroid evalua-
tion. A BM biopsy was performed, and the major patho-
logical findings were several compact aggregates of
CD25+/CD117+/tryptase+ MC, representing around 15%
of the cellularity (Fig. 1, upper panel), increased amount
of plasma cells (8% of the cellularity with mild increase
in lambda monotypic elements), and mild focal fibrosis.
Upon these data, the initial diagnosis was ASM with asso-
ciated monoclonal gammopathy of undetermined signifi-
cance (MGUS), secondary osteoporosis, and history of
anaphylaxis after hymenoptera sting.
The patient was then referred to our Multidisciplinary
Outpatients Clinics for Mastocytosis. We repeated the
BM aspirate, detecting around 1% MC, 80% of them with
spindle-shape morphology and abnormal distribution of
granules (atypical MC type I), corroborating the diagnosis
of SM. Multiparametric flow cytometric immunopheno-
type on BM documented the presence of CD2+ and
CD25+ MC (0.01% of total CD45+ cells), and the KIT
D816V point mutation was detected by ARMS-qPCR
analysis both in BM and in PB [7]. Subpopulations of
nucleated cells were purified by fluorescence-activated
cell-sorting (FACS), and the KIT mutation was identified
in MC, neutrophils, monocytes, and eosinophils, but not
in lymphocytes.
The discordance between the low MC burden and the
extension of bone involvement prompted us to perform a
Table 1. Laboratory data at diagnosis.
Parameters Value Normal values, range
White blood cell, 109/L 11.87 4.3–10
Neutrophils, % 66.7 43–70
Lymphocytes, % 16.6 25–44
Monocytes, % 9.8 2–12
Eosinophils, % 0.6 0–5
Basophils, % 0 0–2
Platelets, 109/L 121 150–400
Hemoglobin, g/dL 14.3 13.5–17
C-reactive protein, mg/dL 124 <5
Lactate dehydrogenase, U/L 906 240–480
M-component IgM/lambda, g/L 3 –
Bence-Jones proteinuria, mg/L 17 –
Serum calcium, mg/dL 10.2 8.41–10.42
Creatinine, mg/dL 0.7 0.59–1.29
Standard urine examination Normal –
Parathyroid hormone, pg/mL 12 6.5–36.8
Vitamin D, ng/mL 25 30–100
Tryptase, ng/mL 13.2 <11.4
(A) (B) (C) (D)
(E) (F) (G) (H)
Figure 1. Histopathology and immunohistochemistry of the first bone marrow biopsy (upper panel, A–D) and of the lytic lesion (lower panel, E–
H). In the first biopsy, H&E staining shows hypercellular areas (A) that correspond to CD117-positive mast cell aggregates (B), which show co-
expression of CD25 (C). CD138 (D) shows an increase in the plasma cell population. In the TC-guided rebiopsy, H&E shows a dense sheet of large
cells (E) expressing the B-cell marker CD20 (F) as well as CD10 (G). The proliferation index as demonstrated by Ki-67 staining (H) is very high.
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CT-guided needle biopsy on a bone lesion of the right
ilium, leading to the diagnosis of CD10+/BCL6+/MUM1+/
BCL2+ diffuse large B-cell lymphoma (DLBCL) without
MC infiltration (Fig. 1, lower panel). The proliferation
index, assessed by staining with the monoclonal MIB1
antibody against the Ki67 antigen, was 80–90%. The very
small size of the targeted biopsy did not allow the investi-
gation of the KIT D816V mutation in that sample. There-
fore, the final diagnosis was SM-AHN: ISM was
identifiable as the provisional WHO variant of bone mar-
row mastocytosis (BMM) [8], and the AHN was classified
as the rare entity of primary bone DLBCL [9, 10].
The patient was treated with two cycles of HyperCVAD
plus rituximab, obtaining only a partial remission. He
then received three cycles of DHAOX plus rituximab, fol-
lowed by stem cell harvest: after this therapy, FDG-PET
demonstrated complete remission of the lymphoma
(Fig. 2), while an iliac crest, nonlesional BM biopsy
showed a stable MC infiltration (10% of the BM cellular-
ity). Autologous stem cell transplantation was performed
after mitoxantrone and melphalan conditioning in March
2014. Monthly treatment with i.v. zolendronate was
administered for 1 year and then every 3–6 months with
supplementation of vitamin D for another year. Presently
(March 2017), the patient is in continuous complete
remission of lymphoma and tryptase levels that are low
and stable (3.5 ng/mL). Of note, the specific
immunotherapy with Apis venom was withheld at
chemotherapy start, with the advice to continue carrying
an epinephrine pen injector.
Diagnosis of SM can be a challenge in patients present-
ing without mastocytosis in the skin (MIS). SM without
MIS has been historically considered an aggressive disease,
with the exception of the BMM variant, an infrequent
indolent form characterized by low MC burden with iso-
lated and scattered or multifocal small-sized atypical MC
aggregates and a normal or only slightly increased tryp-
tase level. However, in recent years, it became evident that
BMM is more frequent than previously described, partic-
ularly in patients presenting with anaphylaxis character-
ized by hypotension without urticaria/angioedema, or
with recurrent mediator-related symptoms [11, 12].
Patients with mastocytosis and anaphylaxis triggered
exclusively by insects display significantly different fea-
tures as compared to other ISM cases, suggesting that
they represent a unique subgroup characterized by
marked male predominance, low incidence of other MC-
related symptoms, and low serum baseline tryptase levels.
Of note, they typically show KIT mutation restricted to
MC, a distinct feature related to a very good prognosis
[13]. However, a KIT D816V mutation multilineage mye-
loid and/or lymphoid involvement may occur in these
patients, indicating a higher number of mutated
hematopoietic progenitors and a higher probability of
progression to advanced disease, such as SM-AHN [14].
The case presented here showed typical characteristics
of BMM (history of anaphylaxis after hymenoptera sting,
slight increase in tryptase, osteoporosis with vertebral
fractures) but the presence of large osteolyses led to a first
incorrect diagnosis of ASM. However, at variance with
the majority of SM patients presenting with osteolysis, he
did not have osteosclerotic lesions. Moreover, the finding
of a very high SUV level in bone lesions represented a
further element against the hypothesis of ASM. 18-FDG
uptake in SM was evaluated in a series of 19 patients, and
pathological BM uptake was documented in nine cases:
the median value of SUV max was 4.6 (range 2–12.2) and
in 78% of patients the pathologic uptake was associated
with diffuse osteosclerosis or a mixed pattern of osteolytic
and osteosclerotic lesions at CT scan. Indeed, all these
patients were affected by SM-AHN or MC sarcoma [15].
In conclusion, we suggest that all patients presenting
with hypotension/syncope triggered by hymenoptera in
the absence of skin symptoms should promptly undergo
BM evaluation in order to early identifying a BMM, typi-
cally associated with normal or only slightly increased
(A) (B)
Figure 2. Axial and coronal fused FDG-PET/CT images in the same
patient before treatment (A) showed hypermetabolic bone lesions in
both humeri, in some ribs, in a lumbar vertebra, in the pelvis (SUV
max 34), and in the left femur. After treatment (B), the FDG uptake
in the same areas was normal. Corresponding CT images depicted
lytic bone lesions.
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tryptase levels [16]. Osteolyses represent a sign of ASM
when they are associated with other signs of high MC bur-
den, such as particularly elevated tryptase levels, and when
concomitant osteosclerotic lesions are present. In this case,
the discordance between the low MC burden and the
extensive bone involvement prompted us to perform a
direct bone biopsy, allowing the diagnosis of an aggressive
lymphoma and avoiding the risk of missing an appropri-
ate intensive chemotherapy treatment, as well as prescrib-
ing an unnecessary cytoreduction for mastocytosis.
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